Considering that at the time of the trigger plamsmatic concentration of E2 was significatively increased in PCOS patients with respect to non-PCOS women (p<0.005; E2 trigger in PCOS is 3064 ± 1138 ng/ml, while E2 trigger in non-PCOS is 1238 ± 669 ng/ml, Table 1), while no difference was observed in P4 levels (p>0.05; P4 trigger in PCOS is 1.07 ± 0.6 ng/ml, while P4 trigger in non-PCOS is 0.93 ± 0.65 ng/ml, Table 1), we decided to perform an ELISA to quantify the E2 in the same FF used for VIP assessment. This evidence concerns the gene VIP and polycystic ovary syndrome.